PDEX

Over the past six months, Pro-Dex's stock price has shown strong performance, outperforming the S&P500 Index by 34.1% and trading significantly higher than its 200-day moving average as of September 2026. In September 2026, Pro-Dex reported Q4 revenue that beat estimates, driven by orthopedic handpiece sales, and announced strong fiscal year 2026 results with EPS and revenues exceeding analyst expectations, leading to an 18.9% stock rally, though these earnings included a $5.7 million one-off gain. In April 2026, Q3 revenue increased by 15% due to higher handpiece shipments. Over the past three months, company insiders, including the CFO and a director, have primarily sold shares.